腺苷调节小胶质细胞极化改善精神分裂症的研究进展
Research Progress of Adenosine Can Improve Schizophrenia via Regulating Microglia Polarization
DOI: 10.12677/IJPN.2021.101001, PDF,   
作者: 邱勤明, 肖 宇, 赵宏宇, 许海云, 张金玲, 方泽漫, 张文晓, 郭凡女, 韩婷婷, 黄庆军*：汕头大学精神卫生中心，广东 汕头；汕头大学医学院，广东 汕头
关键词: 小胶质细胞；神经炎症；髓鞘修复；腺苷；精神分裂症；Microglia； Neuroinflammation； Myelin Restoration； Adenosine； Schizophrenia
摘要: 小胶质细胞作为神经炎症的初始细胞，在中枢神经系统(central nervous system, CNS)免疫中占有重要地位。腺苷是CNS中的重要调节物质，可通过与小胶质细胞中的受体结合发挥作用。有研究表明，小胶质细胞与腺苷结合改变表型，有助于修复损伤的髓鞘，拮抗精神病样症状。本文主要综述腺苷特性、相关分类、小胶质细胞的特性、表型、相关炎症因子以及其与精神分裂症髓鞘修复相关方面的研究进展。为以“小胶质细胞表型”为靶点，开发腺苷系统的新型药物治疗精神分裂症提供参考。
Abstract: Microglia cells, as the initial cells of neuroinflammation, play an important role in central nervous System (CNS) immunity. Adenosine is an important regulator in CNS, which can play its role by binding to receptors in microglia cells. Studies have shown that the phenotype of microglia cells can be changed by binding to adenosine, which contribute to rebuilding damaged myelin sheath and antagonizing psychotic symptoms. This article made a systemic review on adenosine, including characteristics and classification, and microglia, including characteristics, phenotype, inflammatory cytokines and the relationship between microglia and myelin repair in schizophrenia. This review will greatly enhance our understanding in the pathophysiology of schizophrenia and thus provide new insight into searching for new targets and medications in treating schizophrenia.
文章引用：邱勤明, 肖宇, 赵宏宇, 许海云, 张金玲, 方泽漫, 张文晓, 郭凡女, 韩婷婷, 黄庆军. 腺苷调节小胶质细胞极化改善精神分裂症的研究进展[J]. 国际神经精神科学杂志, 2021, 10(1): 1-6. https://doi.org/10.12677/IJPN.2021.101001

参考文献

[1] Gouvêa-Junqueira, D., Falvella, A.C.B., Antunes, A.S.L.M., Seabra, G., Brandão-Teles, C., Martins-de-Souza, D., et al. (2020) Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. Front Psychia-try, 11, 379. [Google Scholar] [CrossRef] [PubMed]
[2] Wylot, B., Mieczkowski, J., Niedziolka, S., Niedziolka, S., Kaminska, B. and Zawadzka, M. (2019) Csf1 Deficiency Dysregulates Glial Responses to Demyelination and Dis-turbs CNS White Matter Remyelination. Cells, 9, 99. [Google Scholar] [CrossRef] [PubMed]
[3] Orihuela, R., McPherson, C.A. and Harry, G.J. (2016) Microglial M1/M2 Polarization and Metabolic States. British Journal of Pharmacology, 173, 649-665. [Google Scholar] [CrossRef] [PubMed]
[4] Yang, X., Xu, S., Qian, Y.and Xiao, Q. (2017) Resveratrol Regulates Mi-croglia M1/M2 Polarization via PGC-1α in Conditions of Neuroinflammatory Injury. Brain, Behavior, and Immunity, 64, 162-172. [Google Scholar] [CrossRef] [PubMed]
[5] Kolosowska, N., Keuters, M.H., Wojciechowski, S., Keksa-Goldsteine, V., Laine, M., Malm, T., et al. (2019) Peripheral Administration of IL-13 Induces Anti-inflammatory Microglial/Macrophage Responses and Provides Neuroprotection in Ischemic Stroke. Neurotherapeutics, 16, 1304-1319. [Google Scholar] [CrossRef] [PubMed]
[6] Shamim, D. and Laskowski, M. (2017) Inhibition of Inflamma-tion Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alz-heimer Disease. Journal of Central Nervous System Disease, 9, Article ID: 1179573517722512. [Google Scholar] [CrossRef] [PubMed]
[7] Bodhankar, S., Lapato, A., Chen, Y., Vandenbark, A.A., Saugstad, J. and Offner, H. (2015) Role for Microglia in Sex Differences after Ischemic Stroke: Importance of M2. Met-abolic Brain Disease, 30, 1515-1529. [Google Scholar] [CrossRef] [PubMed]
[8] Müller, N. (2018) Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Schizophrenia Bulletin, 44, 973-982. [Google Scholar] [CrossRef] [PubMed]
[9] Laskaris, L.E., Di Biase, M.A., Everall, I., Chana, G., Christopoulos, A., Skafidas, E., et al. (2016) Microglial Activation and Progressive Brain Changes in Schizophrenia. British Journal of Pharmacology, 173, 666-680. [Google Scholar] [CrossRef] [PubMed]
[10] Gingele, S., Merkel, L., Prajeeth, C.K., Kronenberg, J., von Hoevel, F.F., Skripuletz, T., et al. (2019) Polarized Microglia Do Not Influence Oligodendrocyte Lineage cells via Astrocytes. Interna-tional Journal of Developmental Neuroscience, 77, 39-47. [Google Scholar] [CrossRef] [PubMed]
[11] Jamwal, S., Mittal, A.,,Kumar, P., Alhayani, D.M. and Al-Aboudi, A. (2019) Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors. Current Pharmaceutical Design, 25, 2892-2905. [Google Scholar] [CrossRef] [PubMed]
[12] Choudhury, H., Chellappan, D.K., Sengupta, P., Pandey, M. and Gorain, B. (2019) Adenosine Receptors in Modulation of Central Nervous System Disorders. Current Pharmaceutical Design, 25, 2808-2827. [Google Scholar] [CrossRef] [PubMed]
[13] Cunha, R.A. (2016) How Does Adenosine Control Neuronal Dysfunction and Neurodegeneration? Journal of Neurochemistry, 139, 1019-1055. [Google Scholar] [CrossRef] [PubMed]
[14] Calovi, S., Mut-Arbona, P. and Sperlágh, B. (2019) Microglia and the Pu-rinergic Signaling System. Neuroscience, 405, 137-147. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, J., Yang, L., Fang, Z., Kong, J., Huang, Q. and Xu, H. (2018) Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain. Journal of Neuroimmune Pharmacology, 13, 412-425. [Google Scholar] [CrossRef] [PubMed]